David A. Siegel Travere Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 967,500 shares of TVTX stock, worth $20 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

967,500

Previous 720,400 34.3%

Holding current value

$20 Million

Previous $10.1 Million 67.23%

% of portfolio

0.04%

Previous 0.02%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$13.65 - $19.85 $3.37 Million - $4.9 Million	247,100 Added 34.3%	967,500 $16.9 Million
Q3 2024 Nov 14, 2024	BUY	$7.89 - $15.21 $1.32 Million - $2.54 Million	167,100 Added 30.2%	720,400 $10.1 Million
Q2 2024 Aug 14, 2024	SELL	$5.26 - $8.28 $772,694 - $1.22 Million	-146,900 Reduced 20.98%	553,300 $4.55 Million
Q1 2024 May 15, 2024	BUY	$7.18 - $9.82 $1.13 Million - $1.55 Million	157,400 Added 29.0%	700,200 $5.4 Million
Q4 2023 Feb 14, 2024	SELL	$5.44 - $9.5 $185,504 - $323,950	-34,100 Reduced 5.91%	542,800 $4.88 Million
Q3 2023 Nov 14, 2023	SELL	$7.64 - $17.25 $824,356 - $1.86 Million	-107,900 Reduced 15.76%	576,900 $5.16 Million
Q2 2023 Aug 14, 2023	SELL	$15.3 - $22.61 $563,040 - $832,048	-36,800 Reduced 5.1%	684,800 $10.5 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $7.49 Million - $9.63 Million	420,500 Added 139.65%	721,600 $16.2 Million
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $1.7 Million - $2.4 Million	92,000 Added 44.0%	301,100 $6.33 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $820,178 - $1.02 Million	35,800 Added 20.66%	209,100 $5.15 Million
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $1.65 Million - $2.36 Million	78,600 Added 83.0%	173,300 $4.2 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $1.11 Million - $1.44 Million	47,000 Added 98.53%	94,700 $2.44 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $1.16 Million - $1.49 Million	47,700 New	47,700 $1.48 Million
Q2 2021 Aug 16, 2021	SELL	$14.11 - $26.4 $1.78 Million - $3.32 Million	-125,900 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$23.37 - $31.77 $740,829 - $1.01 Million	-31,700 Reduced 20.11%	125,900 $3.14 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $3.02 Million - $4.39 Million	157,600 New	157,600 $4.3 Million

Others Institutions Holding TVTX

# of Institutions

213

Shares Held

94.1M

Call Options Held

1.2M

Put Options Held

778K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.33B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account